Minimum Investment
About Company
Company Name: Symbiotec Pharmalab Limited
Industry / Sector: Pharmaceuticals & Biotechnology
Founded Year: 2002 (evolved from a 1995 lab-scale operation)
Promoters: Anil Satwani, Kashish Satwani, Sushil Satwani, Satwani Holdings LLP
Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. With over 30 years of industry experience, it has evolved from a lab-scale steroidal hormone API manufacturer into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the US FDA, EU-GMP, and other global regulatory organisations. It operates two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 MT and fermentation capacity of 300 kilolitres.
IPO Basic Details
| Company Name | Symbiotec Pharmalab Limited |
| IPO Type | Mainboard IPO |
| Price Band | ₹938 – ₹988 |
| Lot Size | 15 Shares |
| Total Issue Size | 1,77,86,442 Equity Shares (₹1,757 Cr) |
IPO Strengths & Risks
Strengths
- Global leadership in corticosteroid and steroidal hormone APIs
- Long-standing relationships with domestic and international customers
- Fully invested, multi-scale, vertically integrated manufacturing platform
- Strong regulatory track record (US FDA, EU-GMP, etc.)
- Continuous investment in R&D and strong technological capabilities
- Ability to leverage scientific expertise to expand addressable market
Risks
- High valuation with P/E of 56.81 (post-IPO), leaving little room for disappointment
- Concentration in the steroid/hormone API segment
- Exposure to regulatory changes in key export markets
- Dependence on raw material availability and pricing
- Foreign exchange rate fluctuations impacting profitability
- Intense competition in the global API market
IPO Important Dates
| IPO Open Date | 24 Aug 2026 |
| IPO Close Date | 27 Aug 2026 |
| Basis of Allotment | 28 Aug 2026 |
| Refund Initiation | Not specified in the source |
| Demat Credit Date | 31 Aug 2026 |
| Listing Date | 01 Sep 2026 |
| Anchor Investor Date | - |
| UPI Mandate Deadline | - |
IPO Objectives
- Capital expenditure for machinery and equipment – -
- Funding working capital requirements – -
- Debt repayment – -
- General corporate purposes – Balance Amount
Investor Reservation
| QIB Quota | Not more than 50% of the Net Offer |
| Retail Quota | Not less than 35.00% of the Net Offer |
| HNI Quota | - |
| Employee Quota | - |
| Shareholder Quota | - |
| Anchor Investor Allocation | - |
Market Lot Details
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 Lot | 15 | ₹14,820 |
| Retail Maximum | 13 Lots | 195 | ₹1,92,660 |
| S-HNI Minimum | 14 Lots | 210 | ₹2,07,480 |
| S-HNI Maximum | 67 Lots | 1,005 | ₹9,92,940 |
| B-HNI Minimum | 68 Lots | 1,020 | ₹10,07,760 |
Key Performance Indicators (KPI)
| ROE | 11.19% |
| ROCE | 11.56% |
| RoNW | - |
| PAT Margin | 12.60% |
| EBITDA Margin | 26.59% |
| EPS | ₹17.82 (Pre-IPO) |
| NAV per share | - |
| Debt to Equity | Not explicitly stated, but total borrowing stood at ₹387.91 Cr as of March 31, 2026 |
| P/E Ratio | - |
| Industry P/E | - |
Company Financial Data
| Period | Assets | Total Income | PAT | EBITDA | Net Worth | Borrowings |
|---|---|---|---|---|---|---|
| FY2026 | ₹1,780.79 Cr | ₹872.26 Cr | ₹109.90 Cr | ₹231.97 Cr | ₹1,158.64 Cr | ₹387.91 Cr |
| FY2025 | ₹1,579.65 Cr | ₹755.98 Cr | ₹96.79 Cr | ₹206.11 Cr | ₹821.15 Cr | ₹540.92 Cr |
| FY2024 | ₹1,294.79 Cr | ₹723.33 Cr | ₹100.06 Cr | ₹177.04 Cr | ₹720.68 Cr | ₹247.21 Cr |
Grey Market Premium
| GMP Price | Not Available |
| Kostak Rate | Not Available |
| Subject to Sauda | Not Available |
| Last Updated | Not Available |
| Estimated Listing Price | TBA |
IPO Subscription Data
| Total Subscription | Pending |
| QIB (Ex Anchor) | Pending |
| HNI Subscription | Pending |
| Retail Subscription | Pending |
| Anchor | - |
IPO Intermediaries
Registrar: MUFG Intime India Pvt. Ltd.
Registrar Website: Not explicitly stated in the source
IPO Lead Manager(s)
Company Information
Address: 385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh - 453331
Website: https://www.symbiotec.com
Email: secretarial@symbiotec.com
Phone: +91 731 667 6405
IPO Documents
Frequently Asked Questions (FAQ)
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.